Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2017

Filed with the SEC on Nov 14, 2017 and accepted by EDGAR at Nov 14, 2017, 08:31 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-07-01 to 2017-09-30$3.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2017-01-01 to 2017-09-30$7.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-07-01 to 2017-09-30−$4.1mus-gaap:OperatingIncomeLoss
Operating income9 months2017-01-01 to 2017-09-30−$10.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-07-01 to 2017-09-30$304us-gaap:InterestExpense
Interest expense9 months2017-01-01 to 2017-09-30$912us-gaap:InterestExpense
Diluted EPS3 months2017-07-01 to 2017-09-30−$0.24us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2017-01-01 to 2017-09-30−$0.78us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2017-01-01 to 2017-09-30−$5.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2017-09-30$9.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-09-30$10.2mus-gaap:AssetsCurrent
Total assetsAt period end2017-09-30$16.1mus-gaap:Assets
Current liabilitiesAt period end2017-09-30$12.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-09-30$15.4mus-gaap:Liabilities
Shareholders' equityAt period end2017-09-30$679.4kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-058607. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.